Emergent BioSolutions Inc. has secured a $62.4 million contract modification from the Administration for Strategic Preparedness and Response, a division of the United States Department of Health and Human Services, for its Botulism Antitoxin Heptavalent (BAT®). This modification is part of an existing 10-year contract and aims to bolster the U.S. biodefense supply by providing antitoxins used in treating symptomatic botulism from various botulinum neurotoxin serotypes in both adults and pediatric patients. Paul Williams, senior vice president at Emergent, emphasized the U.S. government's ongoing commitment to stockpiling BAT®, highlighting the importance of medical countermeasures in protecting military and civilian populations and strengthening global emergency preparedness.